Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: A comparative retrospective database study

BMJ Open

Volumn 3, Issue 4, 2013, Pages

  Wang, Li ^a   Wei, Wenhui ^b   Miao, Raymond ^b   Xie, Lin ^a   Baser, Onur ^a,c  

^a STATINMED RESEARCH   (United States)

^b SANOFI   (France)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OCCUPATIONAL HEALTH; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS;

EID: 84877659674     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-002348     Document Type: Article

References (46)

1. US Centers for Disease Control and Prevention. National diabetes fact sheet 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf (accessed 18 Jun 2012).
2. Morsanutto A, Berto P, Lopatriello S, et al. Major complications have an impact on total annual medical cost of diabetes: results of a database analysis. J Diabetes Complications 2006;20:163-9.
3. Kim S. Burden of hospitalizations primarily due to uncontrolled diabetes: implications of inadequate primary healthcare in the United States. Diabetes Care 2007;30:1281-2. (Pubitemid 46684664)
4. Durden ED, Alemayehu B, Bouchard JR, et al. Direct health care costs of patients with type 2 diabetes within a privately insured employed population, 2000 and 2005. J Occup Environ Med 2009;51:1460-5.
5. American Diabetes Association. Economic costs of diabetes in the U.S. In 2007. Diabetes Care 2008;31:596-615.
6. Gillum LA, Gouveia C, Dorsey ER, et al. NIH disease funding levels and burden of disease. PLoS ONE 2011;6:e16837.
7. Mattila TK, De Boer A. Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus. Drugs 2010;70:2229-45.
8. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011;33:74-109.
9. Gibson TB, Song X, Alemayehu B, et al. Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care 2010;16:589-600.
10. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30. (Pubitemid 40847288)
11. Stuart B, Davidoff A, Lopert R, et al. Does medication adherence lower Medicare spending among beneficiaries with diabetes? Health Serv Res 2011;46:1180-99.
12. Sprince NL, Pospisil S, Peek-Asa C, et al. Occupational injuries among workers with diabetes: the National Health Interview Survey, 1997-2005. J Occup Environ Med 2008;50:804-8.
13. Rizzo JA, Abbott TA III, Pashko S. Labour productivity effects of prescribed medicines for chronically ill workers. Health Econ 1996;5:249-65. (Pubitemid 126482630)
14. Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-16.
15. Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: A meta-Analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28:950-5. (Pubitemid 40434505)
16. Mullins P, Sharplin P, Yki-Järvinen H, et al. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007; 29:1607-19. (Pubitemid 47496243)
17. Home PD, Fritsche A, Schinzel S, et al. Meta-Analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab 2010;12:772-9.
18. Riddle MC. Making the transition from oral to insulin therapy. Am J Med 2005;118(Suppl 5A):14S-20S. (Pubitemid 40585811)
19. Clement S, Bowen-Wright H. Twenty-four hour action of insulin glargine (Lantus) may be too short for once-daily dosing: A case report. Diabetes Care 2002;25:1479-80.
20. Esposito K, Chiodini P, Capuano A, et al. Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes. Diabetes Care 2012;35:2698-705.
21. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type2 diabetes: A patient-centered approach. Diabetes Care 2012;35:1364-79.
22. Esposito K, Capuano A, Giugliano D. Humalog (lispro) for type 2 diabetes. Expert Opin Biol Ther 2012;12:1541-50.
23. Cooke CE, Lee HY, Tong YP, et al. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin 2010;26:231-8.
24. Jansà M, Hernández C, Vidal M, et al. Multidimensional analysis of treatment adherence in patients with multiple chronic conditions. A cross-sectional study in a tertiary hospital. Patient Educ Couns 2010;81:161-8.
25. Davis SN, Wei W, Garg S. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract 2011;17:845-52.
26. Xie L, Wei W, Pan C, et al. A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens. Adv Ther 2011;28:1000-11.
27. Xie L, Zhou S, Wei W, et al. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulinglargine-treated patients with type 2 diabetes mellitus. Diabetes Technol Ther 2013;15:230-6.
28. Baser O, Bouchard J, DeLuzio T, et al. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe. Adv Ther 2010;27:94-104.
29. Zhao Y, Campbell CR, Fonseca V, et al. Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care 2012;35:1126-32.
30. Goetzel RZ, Long SR, Ozminkowski RJ, et al. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med 2004;46:398-412. (Pubitemid 38469017)
31. Hawkins K, Wang S, Rupnow MF. Indirect cost burden of migraine in the United States. J Occup Environ Med 2007;49:368-74. (Pubitemid 46624354)
32. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
33. Rhoads GG, Dain MP, Zhang Q, et al. Two-year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetes. Diabetes Obes Metab 2011;13:711-17.
34. Clissold R, Clissold S. Insulin glargine in the management of diabetes mellitus: An evidence-based assessment of its clinical efficacy and economic value. Core Evid 2007;2:89-110.
35. Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Pharmacoeconomics 2007;25:253-66. (Pubitemid 46376834)
36. Brändle M, Azoulay M, Greiner RA. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther 2007;45:203-20. (Pubitemid 46629383)
37. Schöffski O, Breitscheidel L, Benter U, et al. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study. J Med Econ 2008;11:695-712.
38. Lee LJ, Yu AP, Johnson SJ, et al. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: A retrospective database analysis. Diabetes Res Clin Pract 2010;87:108-16.
39. Brändle M, Azoulay M, Greiner RA. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland. Int J Clin Pharmacol Ther 2011;49:217-30.
40. Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life and adherence. Clin Med Res 2008;6:54-67.
41. Wei W, Pan C, Xie L, et al. Association of treatment persistence and adherence with real-world outcomes among insulin-treated patients with type 2 diabetes mellitus (T2DM). Diabetes 2012;61:A4.
42. Gore M, Brandenburg NA, Hoffman DL, et al. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. J Pain 2006;7:892-900. (Pubitemid 44854739)
43. Musich S, Hook D, Baaner S, et al. The association of two productivity measures with health risks and medical conditions in an Australian employee population. Am J Health Promot 2006;20:353-63. (Pubitemid 43726095)
44. Sullivan PW, Ghushchyan V, Wyatt HR, et al. Productivity costs associated with cardiometabolic risk factor clusters in the United States. Value Health 2007;10:443-50. (Pubitemid 350013264)
45. Sullivan PW, Ghushchyan V, Ben-Joseph RH. The effect of obesity and cardiometabolic risk factors on expenditures and productivity in the United States. Obesity (Silver Spring) 2008;16:2155-62.
46. Kannan H, Thompson S, Bolge SC. Economic and humanistic outcomes associated with comorbid type-2 diabetes, high cholesterol and hypertension among individuals who are overweight or obese. J Occup Environ Med 2008;50:542-9. (Pubitemid 351677637)